Sarcoma, Soft Tissue
55
6
7
28
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
11 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.3%
4 terminated out of 55 trials
87.5%
+1.0% vs benchmark
5%
3 trials in Phase 3/4
39%
11 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (55)
Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
Colorectal Resections in Patients With Retroperitoneal Sarcoma
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life
Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
Trabectedin Maintenance Post 1st-line in STS
Alimta Plus Gemcitabine for Advanced Sarcoma